Evaluation from Japanese pharmaceutical company

Evaluation from Japanese pharmaceutical company

It has been about five years now since we began outsourcing our clinical studies to Linical. As the number of studies they have handled for us has gradually increased, they have become very important and valuable to our company. As clinical development is becoming more and more globalized, we need to maximize speed and product value at the same time, on a global level. For this reason, we frequently need to impose stringent requirements on CROs regarding study design and implementation timing. We’re grateful that Linical is able to deal with our demands reliably and flexibly. Another good point about Linical is that their governance is very good—even when we request changes across multiple studies, they can always adapt rapidly. A key attraction of Linical for us is that they can handle global studies from Japan, which means that even when we have to conduct studies overseas, we can still run our CRO management in the same way we do for Japanese studies. As a growing company that employs a lot of young CRAs, we expect Linical to get bigger and better over time.